Onyx Biotec Limited is coming up with an IPO with a fresh issue of 48,10,000 shares worth INR 29.34 crores. The company aims to upgrade manufacturing units, enhance packaging, repay loans, and support corporate purposes.
Onyx Biotec IPO – Important Dates
| Onyx Biotec Limited IPO Date | November 13, 2024 to November 18, 2024 |
| Onyx Biotec Limited IPO Listing Date | November 21, 2024 |
| Onyx Biotec Limited IPO Price | INR 58-61 per share |
| Onyx Biotec Limited IPO Lot Size | 2000 Shares |
| Onyx Biotec Limited IPO Total Issue Size | INR 29.34 crores |
| Onyx Biotec Limited IPO Basis of Allotment | November 19, 2024 |
| Onyx Biotec Limited IPO Initiation of Refunds | November 20, 2024 |
| Onyx Biotec Limited IPO Credit of Shares to Demat | November 20, 2024 |
| Onyx Biotec Limited IPO Issue Type | Book Built Issue IPO |
| Onyx Biotec Limited IPO Listing At | NSE SME |
Read more about Onyx Biotec Limited IPO GMP
Onyx Biotec Limited IPO – Company Profile
Onyx Biotec Limited, established in 2010, specializes in sterile pharmaceutical products and manufactures sterile water for dry powder injections. They provide end-to-end manufacturing solutions and regulatory support, ensuring high-quality, FDA-compliant standards.
The manufacturing facility has a daily capacity of 6,38,889 Sterile Water units, 40,000 dry powder injections, and 26,667 dry syrups. Equipped with modern equipment, it meets WHO-GMP standards and undergoes regular audits and inspections.
With robust quality control, GMP adherence, and ISO standards, the company ensures innovative, cost-effective, and consistent product quality. Repeat orders from 35 clients highlight its reliability, expertise, and commitment to customer satisfaction.
Onyx Biotec Ltd IPO Fundamental Analysis
Onyx Biotec Limited’s financial analysis reveals a mixed performance. Revenue declined, liabilities and assets grew, but profitability, EPS, RoNW, and liquidity weakened, raising concerns over financial health, inventory management, and increased debt reliance.
- Revenue Trend: The revenue decreased from ₹4,486.14 lakhs in March 2022 to ₹3,948.19 lakhs in March 2023. The revenue for the current year’s 2-month period ending May 2024 is INR 1,052.81 lakhs.
- Equity and Liabilities: Both equities and liabilities have shown a consistent increase over the periods, reflecting potential growth and expansion. However, the debt-equity ratio has increased, indicating rising reliance on debt financing.
- Profitability: The profit after tax (PAT) has significantly decreased from ₹335.29 lakhs in March 2022 to ₹130.77 lakhs by May 2024. This decline in profitability could be a source of concern among investors.
- Earnings per Share (EPS): The diluted EPS has reduced from ₹2.84 in March 2022 to ₹0.98 by May 2024, reflecting lower earnings per share for investors.
- Return on Net Worth (RoNW): The RoNW has reduced from 20.47% to 4.99%, indicating a decrease in the company’s ability to generate returns on shareholder equity.
- Financial Position: Total assets have increased, suggesting potential business growth. However, the current ratio has decreased, indicating weakening liquidity and potential challenges in meeting short-term obligations.
- Inventory Turnover Ratio: There’s a significant decrease in the Inventory Turnover Ratio, which might suggest slower sales or inefficient inventory management.
Onyx Biotec IPO Financial Analysis
| Particular | As of 31 March 2022 | As of 31 March 2023 | As of 31 May 2024 |
| Revenue (₹ in lakhs) | 4,486.14 | 3,948.19 | 1,052.81 |
| Equity (₹ in lakhs) | 1,637.59 | 1,820.16 | 2,618.64 |
| Expenses (₹ in lakhs) | 4,118.55 | 3,706.99 | 879.15 |
| Profit and Loss After Tax (₹ in lakhs) | 335.29 | 184.46 | 130.77 |
| Diluted EPS only (₹) | 2.84 | 1.56 | 0.98 |
| Return on Net Worth (%) | 20.47 | 10.13 | 4.99 |
| NAV per Equity Share (₹) | 13.87 | 15.42 | 19.66 |
| Total Assets (in lakhs) | 3,683.84 | 5,872.36 | 7,476.57 |
| Total Liabilities (in lakhs) | 2,046.25 | 4,052.2 | 4,857.93 |
| Debt Equity Ratio | 0.75 | 1.61 | 1.21 |
| Current Ratio (in times) | 1.44 | 0.72 | 1.38 |
| Inventory Turnover Ratio | 14.01 | 8.42 | 1.13 |
Onyx Biotec Limited IPO Peer Comparison
Onyx Biotec Limited, Suven Pharma, and JB Chemicals are pharmaceutical companies with diverse market capitalizations. Each company has varying stock metrics, profitability ratios, and valuations, highlighting their unique positions within the industry.
| Company | Revenue from Operations (₹ in lakhs) | Face Value per Equity Share (₹) | P/E Ratio | EPS (Basic & Diluted) (₹) | RoNW (%) | NAV (₹ per share) |
| Onyx Biotec Limited | 5,374.88 | 10 | – | 2.28 | 12.19 | 18.67 |
| Suven Pharma | 1,05,135.37 | 1 | 83.92 | 11.80 | 14.64 | 375.82 |
| JB Chemicals | 3,48,418.38 | 1 | 53.63 | 35.66 | 18.90 | 188.37 |
Onyx Biotec Ltd IPO Objective
The main objective of Onyx Biotec Limited is to upgrade manufacturing units for large-volume parentals, set up high-speed packaging for dry powder injections, and repay certain loans to strengthen its financial position.
- Upgradation of existing Unit I to manufacture large volume parentals for intravenous use: The company intends to utilize INR 6.07 crores from the net proceeds for upgrading its existing manufacturing Unit I to produce large volume parentals for intravenous use, expanding its product portfolio and enhancing production capacity.
- Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections: The company plans to utilize INR 1.24 crores from the net proceeds to set up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections, improving efficiency, cost-effectiveness, and product safety.
- Prepayment or repayment of all or a portion of certain loans availed by their company: The company aims to utilize INR 12 crores from the net proceeds for the full or partial repayment of borrowings, reducing debt, lowering servicing costs, improving leverage, and enabling further business growth and expansion.
- General Corporate Purposes: The company will deploy funds for general corporate purposes, including strategic initiatives, general procurement, brand building, strengthening marketing activities, and addressing ongoing corporate exigencies or other purposes as needed.
Onyx Biotec IPO Risks And Challenges
Onyx Biotec Limited’s risk includes regional exposure to economic, political, and environmental factors, challenges in meeting quality standards, procurement issues, and compliance with global regulations, which may lead to operational disruptions and financial setbacks.
- The company’s operations are concentrated in Solan, Himachal Pradesh, exposing it to regional economic, political, and environmental risks, including natural disasters and policy changes, which could adversely affect its business, operations, and financial condition.
- As a contract manufacturer, the company faces risks related to meeting quality standards, procurement of materials, and potential product recalls or legal claims. Non-compliance or quality issues may disrupt operations and harm its financial performance.
- The company must comply with global and local regulations, including WHO GMP standards. Non-compliance with regulatory or contractual requirements could lead to sanctions, operational disruptions, and legal claims, negatively impacting business and financial performance.
Onyx Biotec Ltd IPO – Industry & Market Potential
India’s pharmaceutical industry is projected to reach US$ 130 billion by 2030 and US$ 450 billion by 2047, driven by exports, domestic growth, government schemes, and increasing global demand, with significant investment in manufacturing and medical devices.
India is a critical player in the global pharmaceutical industry, producing 8% of global APIs, leading in CRAMS and biosimilars, and dominating formulation exports. The pharmaceutical packaging market is expected to grow significantly by 2030.
India’s pharmaceutical industry ranks third globally in production, exporting to over 200 countries. With US$ 27.9 billion in exports (FY24), the sector is increasing, aiming for a US$ 50 billion medical devices market by 2030.
Onyx Biotec Limited IPO – Type of Offer
Onyx Biotec Limited is coming up with an IPO with a fresh issue of 48,10,000 shares worth INR 29.34 crores. The company aims to upgrade manufacturing units, enhance packaging, repay loans, and support corporate purposes.
Onyx Biotec IPO Offer Size
The offer size of Onyx Biotec Limited is INR 29.34 crores, consisting of a fresh issue of 48,10,000 shares worth INR 29.34 crores. The company aims to upgrade manufacturing units, enhance packaging, repay loans, and support corporate purposes.
Onyx Biotec SME IPO Allotment Structure
Onyx Biotec Limited’s allocation will be as follows: 49.89% for Qualified Institutional Buyers (QIB), 15.07% for Non-Institutional Investors (NII), and 35.04% for Retail Individual Investors (RII) according to SEBI regulations. 244,000 shares are reserved for market makers.
● Qualified Institutional Buyers (QIB): As per SEBI regulations, 49.89% of the shares offered through the IPO will be reserved for Qualified Institutional Buyers. These include entities such as banks, mutual funds, and insurance companies.
● Non-Institutional Investors (NII): 15.07% of the shares will be reserved for Non-Institutional Investors. These typically include corporate bodies or individuals investing more than Rs.2 lakhs.
● Retail Individual Investors (RII): The remaining 35.04% of the shares will be allotted to Retail Individual Investors. These individual investors apply for shares with a total value of less than Rs.2 lakhs.
● Market Maker Reservation: A portion of shares, i.e. 244,000 shares, are reserved for market makers.
How to apply for Onyx Biotec IPO?
To apply for the Onyx Biotec Limited IPO through Alice Blue, follow these steps:
Open a Demat and Trading Account: If you don’t have one already, you must open a Demat and trading account with Alice Blue.
- Check for IPO Details: Once your account is active, you can check for the Onyx Biotec Limited IPO details in the IPO section of the Alice Blue platform.
- Place the Bid: Enter the number of shares you wish to buy and place your bid within the IPO’s price band.
- Submit the Application: Confirm all your details and submit your application.
You can apply for the Onyx Biotec Limited IPO at Alice Blue in just a few clicks!
Check Allotment Status: After the allotment process, you can check the allotment status to see if you have received any shares.
Please note that the allotment of shares is not guaranteed and will depend on the demand for the IPO.
How do you check Onyx Biotec IPO Allotment Status?
Checking the allotment status of an IPO in Alice Blue is usually straightforward. Please follow these general steps:
- Log in to your Alice Blue Account: You can do this through the Alice Blue website or the trading app.
- Navigate to the Portfolio or IPO Section: This might differ based on the layout of Alice Blue’s platform, but generally, you can find the status of your IPO application under the ‘Portfolio’ or ‘IPO’ section.
- Find the IPO Allotment Status: Look for a sub-section called ‘IPO Allotment Status’ or something similar. This is where you can see the status of the IPOs you have applied for.
- Select the Onyx Biotec Limited IPO: If you have applied for multiple IPOs, there might be a dropdown menu or a list where you can select the IPO you are interested in. Select the Onyx Biotec Limited IPO.
- Check the Status: The status of your application should be displayed here. If the shares have been allocated to you, it would be mentioned here.
If you face any issues, we request you reach out to our customer support team at Alice Blue for detailed assistance.
Apart from Alice Blue, there are other ways to check the allotment status of the Onyx Biotec Limited IPO:
● Registrar’s Website: Visit the website of MAS Services Limited, the registrar of the Onyx Biotec Limited IPO. On the homepage, look for the ‘IPO Allotment Status’ option. You must enter your PAN, application, or Demat account number to check your allotment status. Click on the ‘Submit’ button to view your IPO allotment status.
● NSE SME: You can also check the allotment status on the official websites of the National Stock Exchange (NSE) Small Medium Exchange (SME). You would need your application number and PAN to check the status.
Please note that the allotment status will only be available after completing the allotment process, a few days after the IPO window closes.
Onyx Biotec Ltd IPO Offer Registrar
The registrar for the Onyx Biotec Limited IPO is Mas Services Limited. They are responsible for ensuring the IPO allotment and refund processes are carried out smoothly.
Contact information for the registrar:
MAS Services Limited
T-34, 2nd Floor, Okhla Industrial Area,
Phase-II New Delhi- 110 020
Telephone: +91 112 638 7281/83, 114 132 0335
E-mail: [email protected]
Website: www.masserv.com
Onyx Biotec IPO – FAQs
1. What is the allotment date of the Onyx Biotec IPO?
The allotment date of the Onyx Biotec is November 19, 2024.
2. What is the price band of the Onyx Biotec IPO?
The price band of the issue is INR 58-61 per share.
3. What is the size of the Onyx Biotec IPO?
The offer size of Onyx Biotec Limited is INR 29.34 crores, consisting of a fresh issue of 48,10,000 shares worth INR 29.34 crores. The company aims to upgrade manufacturing units, enhance packaging, repay loans, and support corporate purposes.
4. What is the listing date of the Onyx Biotec IPO?
The listing date of the Onyx Biotec is November 21, 2024.
5. Where is the Onyx Biotec IPO Getting Listed?
Onyx Biotec is getting listed on the National Stock Exchange (NSE) and the Small Medium Exchange (SME).
6. What are the open and close dates of the Onyx Biotec Limited IPO?
The open and close dates of the Onyx Biotec Limited are November 13, 2024 and November 18, 2024.
7. How to apply for Onyx Biotec Ltd IPO in Alice Blue?
To apply for the Onyx Biotec Limited IPO through Alice Blue, follow these steps:
Open a Demat and Trading Account: If you don’t have one already, you must open a Demat and trading account with Alice Blue.
- Check for IPO Details: Once your account is active, you can check for the Onyx Biotec Limited IPO details in the IPO section of the Alice Blue platform.
- Place the Bid: Enter the number of shares you wish to buy and place your bid within the IPO’s price band.
- Submit the Application: Confirm all your details and submit your application.
You can apply for the Onyx Biotec Limited IPO at Alice Blue in just a few clicks!
Check Allotment Status: After the allotment process, you can check the allotment status to see if you have received any shares.
Please note that the allotment of shares is not guaranteed and will depend on the demand for the IPO.
8. Who is the Book Runner for the Onyx Biotec IPO?
The Book Runner for the Onyx Biotec is Horizon Management Private Limited.
